Home Recalls D-0387-2019
Class II · Moderate risk Completed Initiated Dec 20, 2018 (8 years ago)
OZURDEX (dexamethasone intravitreal implant) 0.7 mg), 1 single-use plastic applicator…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
GMP Deviations: A silicone particulate was noted in Ozurdex.
What was recalled
OZURDEX (dexamethasone intravitreal implant) 0.7 mg), 1 single-use plastic applicator contained within carton, Rx only, Allergan Inc Irvine, CA 92612, NDC 0023-3348-07
Recalling firm Allergan, PLC.
NDC code 0023-3348-07
Origin NJ, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-0387-2019
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Other Dexamethasone recalls
See all
Class II · Moderate risk Ongoing Feb 4, 2026
Reason Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were…
Class II · Moderate risk Ongoing Dec 18, 2025
Reason Presence of particulate matter - Glass like particles.
Class II · Moderate risk Ongoing Dec 18, 2025
Reason Presence of particulate matter - Glass like particles.
Class II · Moderate risk Ongoing Aug 13, 2025
Reason Temperature Abuse
Class II · Moderate risk Ongoing Apr 15, 2025
Reason Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024…